Praxis Precision Medicines Inc (PRAX) Q3 2024 Earnings Call Highlights: Strong Cash Position ... [Yahoo! Finance]
Praxis Precision Medicines, Inc. (PRAX)
Company Research
Source: Yahoo! Finance
General and Administrative (G&A) Expenses: $15.3 million in Q3 2024. Operating Cash Spend: $27.7 million in Q3 2024. Cash, Cash Equivalents, and Marketable Securities: $411.2 million as of the end of Q3 2024. Cash at December 31, 2023: $81.3 million. Cash Runway: Supports operations into 2027. Warning! GuruFocus has detected 4 Warning Signs with PRAX. Release Date: November 06, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript Praxis Precision Medicines Inc ( NASDAQ:PRAX ) is advancing four programs towards registration, representing a substantial multi-billion dollar opportunity. The phase three study for Ulixacaltamide in essential tremor is progressing well, with results expected in Q1 2025. Positive top-line results were reported for Vormatrigine in a phase two trial, showing a 46% reduction in motor seizures versus placebo. The company has a strong balance sheet with $411.2 million in cash, supporting o
Show less
Read more
Impact Snapshot
Event Time:
PRAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PRAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PRAX alerts
High impacting Praxis Precision Medicines, Inc. news events
Weekly update
A roundup of the hottest topics
PRAX
News
- Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet SyndromeGlobeNewswire
- Praxis Precision Medicines, Inc. (NASDAQ: PRAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.MarketBeat
- GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners [Yahoo! Finance]Yahoo! Finance
- Praxis Precision Medicines to Present at Upcoming December Investor ConferencesGlobeNewswire
PRAX
Earnings
- 11/6/24 - Miss
PRAX
Sec Filings
- 11/19/24 - Form 4
- 11/19/24 - Form 4
- 11/15/24 - Form 4
- PRAX's page on the SEC website